Literature DB >> 20368572

Testis cancer survivors' health behaviors: comparison with age-matched relative and demographically matched population controls.

Eileen H Shinn1, Richard J Swartz, Bob B Thornton, Philippe E Spiess, Louis L Pisters, Karen M Basen-Engquist.   

Abstract

PURPOSE: To determine the prevalence rate of health behaviors in testis cancer survivors and to determine whether the rate of health behaviors in survivors was significantly different than those of their age-matched relative controls and a population-based control group matched for age, sex, education, and income. PATIENTS AND METHODS: The health behaviors of 162 testis cancer survivors were compared with their age-matched relative controls (n = 74) and an age-, sex-, education-, and income-matched population-based control group (n ranged from 1,123 to 9,775). Health behaviors were assessed with the telephone-administered Behavioral Risk Factor and Surveillance Survey.
RESULTS: Nearly one in five testis cancer survivors reported current smoking and one third reported problem drinking. Only 11% reported having at least five servings of fruits and vegetables per day. Compared with their relative controls, the survivors were more likely to engage in regular exercise. For those participants who drank, survivors were twice as likely to engage in problem drinking and averaged a higher number of drinks compared to their Centers for Disease Control (CDC) controls. Survivors were also half as likely to have at least five servings of fruits and vegetables per day compared with the CDC controls.
CONCLUSION: The overall picture regarding testis cancer survivors' health behaviors was mixed compared with the relative and CDC control groups. Our results suggest that reduced alcohol use and increased fruit and vegetable consumption may be important targets for future disease prevention in testis cancer survivors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20368572      PMCID: PMC2860440          DOI: 10.1200/JCO.2009.23.9608

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  24 in total

1.  Risk of second malignant neoplasms among long-term survivors of testicular cancer.

Authors:  L B Travis; R E Curtis; H Storm; P Hall; E Holowaty; F E Van Leeuwen; B A Kohler; E Pukkala; C F Lynch; M Andersson; K Bergfeldt; E A Clarke; T Wiklund; G Stoter; M Gospodarowicz; J Sturgeon; J F Fraumeni; J D Boice
Journal:  J Natl Cancer Inst       Date:  1997-10-01       Impact factor: 13.506

2.  The graying of testis cancer patients: what have we learned?

Authors:  Dean F Bajorin
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

3.  Study of anxiety disorder and depression in long-term survivors of testicular cancer.

Authors:  Alv A Dahl; Carl Fredrik Haaland; Arnstein Mykletun; Roy Bremnes; Olav Dahl; Olbjørn Klepp; Erik Wist; Sophie D Fosså
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

4.  Health status of long-term cancer survivors: results from an Australian population-based sample.

Authors:  Elizabeth G Eakin; Danny R Youlden; Peter D Baade; Sheleigh P Lawler; Marina M Reeves; Jane S Heyworth; Lin Fritschi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-10       Impact factor: 4.254

5.  Blood pressure and body mass index in long-term survivors of testicular cancer.

Authors:  H Sagstuen; N Aass; S D Fosså; O Dahl; O Klepp; E A Wist; T Wilsgaard; R M Bremnes
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

6.  Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer.

Authors:  Alexandra W van den Belt-Dusebout; Janine Nuver; Ronald de Wit; Jourik A Gietema; Wim W ten Bokkel Huinink; Patrick T R Rodrigus; Erik C Schimmel; Berthe M P Aleman; Flora E van Leeuwen
Journal:  J Clin Oncol       Date:  2006-01-20       Impact factor: 44.544

7.  Health behaviors of cancer survivors: examining opportunities for cancer control intervention.

Authors:  Keith M Bellizzi; Julia H Rowland; Diana D Jeffery; Timothy McNeel
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

8.  Cardiovascular morbidity in long-term survivors of metastatic testicular cancer.

Authors:  M T Meinardi; J A Gietema; W T van der Graaf; D J van Veldhuisen; M A Runne; W J Sluiter; E G de Vries; P B Willemse; N H Mulder; M P van den Berg; H S Koops; D T Sleijfer
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

9.  The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample.

Authors:  Lene Thorsen; Wenche Nystad; Hein Stigum; Olav Dahl; Olbjørn Klepp; Roy M Bremnes; Erik Wist; Sophie D Fosså
Journal:  Support Care Cancer       Date:  2005-03-09       Impact factor: 3.603

10.  The correspondence between coronary heart disease mortality and risk factor prevalence among states in the United States, 1991-1992.

Authors:  T Byers; R Anda; D McQueen; D Williamson; A Mokdad; M Casper; E Ford; J Marks
Journal:  Prev Med       Date:  1998 May-Jun       Impact factor: 4.018

View more
  11 in total

1.  Recent developments in the management of germ cell tumors.

Authors:  Pavlos Msaouel; Mehmet A Bilen; Miao Zhang; Matthew Campbell; Jennifer Wang; Shi-Ming Tu
Journal:  Curr Opin Oncol       Date:  2017-05       Impact factor: 3.645

2.  Erratum to: Dendritic cells as therapeutic targets in neuroinflammation.

Authors:  Felix Luessi; Frauke Zipp; Esther Witsch
Journal:  Cell Mol Life Sci       Date:  2016-07       Impact factor: 9.261

3.  Testicular germ cell tumor: Short and long-term side effects of treatment among survivors.

Authors:  Thierry Gil; Spyridon Sideris; Fouad Aoun; Roland van Velthoven; Nicolas Sirtaine; Marianne Paesmans; Lieveke Ameye; Ahmad Awada; Daniel Devriendt; Alexandre Peltier
Journal:  Mol Clin Oncol       Date:  2016-07-14

4.  Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients.

Authors:  Rainer Souchon; Michael Hartmann; Susanne Krege; Anja Lorch; Frank Mayer; Maria De Santis; Silke Gillessen; Jörg Beyer; Richard Cathomas
Journal:  Strahlenther Onkol       Date:  2011-02-21       Impact factor: 3.621

5.  [Follow-up of testicular germ cell cancer patients: interdisciplinary evidence-based recommendations].

Authors:  M Hartmann; S Krege; R Souchon; M De Santis; S Gillessen; R Cathomas
Journal:  Urologe A       Date:  2011-07       Impact factor: 0.639

6.  Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study.

Authors:  Chunkit Fung; Sophie D Fossa; Michael T Milano; Jan Oldenburg; Lois B Travis
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

7.  Exploring the spectrum of late effects following radical orchidectomy for stage I testicular seminoma: a systematic review of the literature.

Authors:  Jennifer A Soon; Angelyn Anton; Javier Torres; Ruth Lawrence; Phillip Parente; Joseph McKendrick; Ian D Davis; Carmel Pezaro
Journal:  Support Care Cancer       Date:  2018-10-22       Impact factor: 3.603

8.  Who tended to continue smoking after cancer diagnosis: the national health and nutrition examination survey 1999-2008.

Authors:  Tung-Sung Tseng; Hui-Yi Lin; Sarah Moody-Thomas; Michelle Martin; Ted Chen
Journal:  BMC Public Health       Date:  2012-09-14       Impact factor: 3.295

Review 9.  Health Behaviors of Childhood Cancer Survivors.

Authors:  Jennifer S Ford; Marie Barnett; Rachel Werk
Journal:  Children (Basel)       Date:  2014-10-22

Review 10.  Caregiver Emotional Burden in Testicular Cancer Patients: From Patient to Caregiver Support.

Authors:  Silvia De Padova; Chiara Casadei; Alejandra Berardi; Tatiana Bertelli; Alessia Filograna; Maria Concetta Cursano; Cecilia Menna; Salvatore Luca Burgio; Amelia Altavilla; Giuseppe Schepisi; Sabrina Prati; Sandra Montalti; Michal Chovanec; Giuseppe Luigi Banna; Luigi Grassi; Michal Mego; Ugo De Giorgi
Journal:  Front Endocrinol (Lausanne)       Date:  2019-05-28       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.